share_log

Wedbush Initiates Coverage On Prime Medicine With Outperform Rating, Announces Price Target of $12

Moomoo 24/7 ·  Apr 2 16:24

Wedbush analyst David Nierengarten initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment